Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin vs Fluconazole for IFI Prevention in Pediatric AML
NCT01307579Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2011
- Primary completion
- Jun 2018
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of caspofungin in invasive fungal infection (IFI), sponsored by Children's Oncology Group. Started Apr 2011; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT01307579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307579.